Binding sites of neutralizing antibody or recombinant ACE2 in S protein
S protein-targeted agents | Name | Binding sites in S protein | References |
---|---|---|---|
Neutralizing antibody | B38 | RBD: R403, D405-E406, Q409, T415-K417, D420-Y421, Y452, L454-N460, Y473-S477, F486-N487, Y489-F490, Q493-G496, Q498, T500-V503, Y505 | [231] |
H4 | RBD | [231] | |
BD-368-2 | RBD | [232] | |
BD-23 | RBD: G446, Y449, L452, T470, E484-F486, Y489-F490, L492-S494, G496, Q498, T500-N501, Y505 | [232] | |
CV30 | RBD: R403, T415-K417, D420-Y421, Y453, L455-N460, Y473-S477, F486-N487, Y489, Q493, T500, G502, Y505 | [233] | |
EY6A | RBD: Y369, F374-S375, F377-K386, N388, L390, P412-G413, D427-F429, L517 | [234] | |
VHH-72 | RBD: Y356-T359, F361-C366, A371-T372, G391-D392, R395, N424, I489, Y494 | [235] | |
S309 | RBD: T333-L335, P337, G339-V341, N343-T345, K356-C361 | [236] | |
4A8 | NTD: R246, K150, K147, H146, W153, Y145, N149 | [237] | |
COV57 | NTD | [238] | |
2-17 | NTD | [238] | |
5-24 | NTD | [238] | |
LY-CoV016 | RBD: R403, D405-E406, R408-Q409, T415-K417, D420-Y421, L455-N460, Y473-S477, F486-N487, Y489, Q493, Y495, N501-G502, G504-Y505 | [230] | |
LY-CoV555 | RBD: TYR32, ARG50, LEU55, TYR92, ARG96, TYR101, GLU102, ARG104, LEU452, GLU484, PHE486, PHE490, GLN493, SER494 | [239] | |
REGN10933 | RBD: R403, K417, Y421, Y453, L455-F456, A475-G476, E484-Y489, Q493 | [240] | |
REGN10987 | RBD: R346, N439-L441, K443-N450, Q498, T500 | [240] | |
BRII-196 | RBD | [230] | |
BRII-198 | RBD | [230] | |
Recombinant ACE2 | APN01 | RBD | [243] |
SBP1 | RBD | [245] |
ACE2: angiotensin-converting enzyme 2; RBD: receptor-binding domain; NTD: N-terminal domain
FX: Conceptualization, Writing—original draft, Visualization, Writing—review & editing, Funding acquisition. YX: Writing—original draft, Visualization, Writing—review & editing. YL: Writing—original draft, Visualization.
The authors declare no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This work was supported by Guangzhou Science and Technology Program Synergistic Innovation Major Project [No.: 201604020146] to FX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.